LTRN

Company Overview — What Does Lantern Pharma Inc. Do?

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Lantern Pharma Inc. (LTRN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Panna L. Sharma and employs approximately 20 people. With a market capitalization of $16M, LTRN is one of the notable companies in the Healthcare sector.

Lantern Pharma Inc. (LTRN) Stock Rating — Avoid (April 2026)

As of April 2026, Lantern Pharma Inc. receives a Avoid rating with a composite score of 18.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.LTRN ranks #4,416 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lantern Pharma Inc. ranks #831 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LTRN Stock Price and 52-Week Range

Lantern Pharma Inc. (LTRN) currently trades at $1.96. The stock gained $0.09 (4.8%) in the most recent trading session. The 52-week high for LTRN is $5.74, which means the stock is currently trading -65.9% from its annual peak. The 52-week low is $2.24, putting the stock -12.5% above its annual trough. Recent trading volume was 402K shares, suggesting relatively thin trading activity.

Is LTRN Overvalued or Undervalued? — Valuation Analysis

Lantern Pharma Inc. (LTRN) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.03x, versus the sector average of 2.75x.

At current multiples, Lantern Pharma Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lantern Pharma Inc. Profitability — ROE, Margins, and Quality Score

Lantern Pharma Inc. (LTRN) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -268.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -159.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LTRN Debt, Balance Sheet, and Financial Health

Lantern Pharma Inc. has a debt-to-equity ratio of 69.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.40x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $8M.

LTRN has a beta of 1.69, meaning it is more volatile than the broader market — a $10,000 investment in LTRN would be expected to move 69.5% more than the S&P 500 on any given day. The stability factor score for Lantern Pharma Inc. is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Lantern Pharma Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lantern Pharma Inc. reported revenue of $0 and earnings per share (EPS) of $-1.57. Net income for the quarter was $-18M. Operating income came in at $-19M.

In FY 2025, Lantern Pharma Inc. reported revenue of $0 and earnings per share (EPS) of $-1.57. Net income for the quarter was $-17M. Operating income came in at $-18M.

In Q3 2025, Lantern Pharma Inc. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q2 2025, Lantern Pharma Inc. reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-4M. Operating income came in at $-5M.

Over the past 8 quarters, Lantern Pharma Inc. has experienced revenue contraction from $0 to $0. Investors analyzing LTRN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LTRN Dividend Yield and Income Analysis

Lantern Pharma Inc. (LTRN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LTRN Momentum and Technical Analysis Profile

Lantern Pharma Inc. (LTRN) has a momentum factor score of 16/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

LTRN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lantern Pharma Inc. (LTRN) ranks #831 out of 838 stocks based on the Blank Capital composite score. This places LTRN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LTRN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LTRN vs S&P 500 (SPY) comparison to assess how Lantern Pharma Inc. stacks up against the broader market across all factor dimensions.

LTRN Next Earnings Date

No upcoming earnings date has been announced for Lantern Pharma Inc. (LTRN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LTRN? — Investment Thesis Summary

The quantitative profile for Lantern Pharma Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 16/100, a headwind for near-term performance. High volatility (stability score 17/100) increases portfolio risk.

In summary, Lantern Pharma Inc. (LTRN) earns a Avoid rating with a composite score of 18.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LTRN stock.

Related Resources for LTRN Investors

Explore more research and tools: LTRN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LTRN head-to-head with peers: LTRN vs AZN, LTRN vs SLGL, LTRN vs VMD.